BEIJING, Jan. 6, 2026 /PRNewswire/ — CGTN published an article focusing on strengthened China-ROK exchanges in women’s and children’s welfare. Highlighting a teaBEIJING, Jan. 6, 2026 /PRNewswire/ — CGTN published an article focusing on strengthened China-ROK exchanges in women’s and children’s welfare. Highlighting a tea

CGTN: China, ROK to strengthen exchanges on welfare for women and children

BEIJING, Jan. 6, 2026 /PRNewswire/ — CGTN published an article focusing on strengthened China-ROK exchanges in women’s and children’s welfare. Highlighting a tea chat between Peng Liyuan, wife of Chinese President Xi Jinping, and Kim Hea Kyung, wife of President of the ROK Lee Jae Myung, the article underscores China’s impressive domestic achievements and steadfast commitment to the global cause.

Peng Liyuan, wife of Chinese President Xi Jinping, chatted over tea with Kim Hea Kyung, wife of President of the Republic of Korea (ROK) Lee Jae Myung, in Beijing on Monday. Kim is accompanying President Lee on his first state visit to China.

During their conversation, the two exchanged views on people-to-people exchanges and shared concerns over the development of women and children. Peng highlighted the importance of close people-to-people ties in state-to-state relations, expressing hope that the two peoples would strengthen mutual understanding through more frequent interactions. Kim commended Peng’s long-term dedication to advancing the welfare of women and children and voiced her readiness to further boost bilateral exchanges in this field.

This shared focus on children’s development was echoed at the governmental level on the same day, with China and the ROK signing a memorandum of understanding on protecting children’s rights and promoting their well-being. Witnessed by both countries’ leaders, the agreement outlines collaboration through policy dialogue, personnel exchanges, and capacity-building programs.

For Peng, the welfare of women and children has long been a core focus of her work. In 2014, she was named a UNESCO Special Envoy for the Advancement of Girls’ and Women’s Education in recognition of her efforts to empower girls and women through quality education. In 2023, she co-launched the “Warm Children’s Hearts, a China-Africa Joint Action” initiative with the Organization of African First Ladies for Development, which has provided health-related assistance to children in over 50 countries across Africa.

China’s broader commitments

China’s extensive efforts to advance the development of women and children have set an exemplary benchmark for global progress in this field. The country ranks among the top-performing upper-middle-income countries globally in key maternal and child health indicators, such as maternal, infant, and under-five mortality rates. The World Health Organization has recognized China as one of the 10 high-performing countries in maternal and child health outcomes.

On the international front, China has unveiled additional commitments to support global women’s development. At the Global Summit of Women in Beijing in October 2025, President Xi announced a series of new initiatives: In the next five years, China will donate another $10 million to UN Women, and earmark a quota of $100 million in China’s Global Development and South-South Cooperation Fund for implementing development cooperation projects for women and girls in collaboration with international organizations. The country will also support 1,000 “small and beautiful” livelihood programs that take women and girls as priority beneficiaries, invite 50,000 women to China for exchange and training programs, and establish a Global Center for Women’s Capacity Building, according to the Chinese president.

China’s contributions have drawn recognition from international organizations. Amakobe Sande, UNICEF Representative to China, noted that China has made remarkable progress in improving the well-being of children in the Global South through a range of development cooperation programs. Gertrude Mongella, secretary-general of the Fourth World Conference on Women, hailed China as an important participant and contributor to global women’s development, thanks to its practical, results-oriented cooperation.

https://news.cgtn.com/news/2026-01-06/China-ROK-to-strengthen-exchanges-on-welfare-for-women-and-children-1JIuMEvu144/p.html

Cision View original content:https://www.prnewswire.com/news-releases/cgtn-china-rok-to-strengthen-exchanges-on-welfare-for-women-and-children-302654642.html

SOURCE CGTN

Market Opportunity
Solchat Logo
Solchat Price(CHAT)
$0,0705
$0,0705$0,0705
-1,26%
USD
Solchat (CHAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26